These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 34371461)

  • 1. Effects of l-carnitine supplementation in patients with childhood-onset epilepsy prescribed valproate.
    Okumura A; Takagi M; Numoto S; Iwayama H; Azuma Y; Kurahashi H
    Epilepsy Behav; 2021 Sep; 122():108220. PubMed ID: 34371461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carnitine supplementation prevents carnitine deficiency caused by pivalate-conjugated antibiotics in patients with epilepsy prescribed valproate.
    Okumura A; Numoto S; Iwayama H; Azuma Y; Kurahashi H
    Epilepsy Behav; 2021 Apr; 117():107883. PubMed ID: 33714931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status.
    Hamed SA; Abdella MM
    Epilepsy Res; 2009 Sep; 86(1):32-41. PubMed ID: 19446440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum carnitine levels of children with epilepsy: Related factors including valproate.
    Okumura A; Kurahashi H; Iwayama H; Numoto S
    Brain Dev; 2019 Jun; 41(6):516-521. PubMed ID: 30827788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association Between the Serum Carnitine Level and Ammonia and Valproic Acid Levels in Patients with Bipolar Disorder.
    Yokoyama S; Yasui-Furukori N; Nakagami T; Miyazaki K; Ishioka M; Tarakita N; Kubo K; Sugawara N; Shimoda K
    Ther Drug Monit; 2020 Oct; 42(5):766-770. PubMed ID: 32482992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of carnitine supplementation in valproate-induced hyperammonaemia.
    Böhles H; Sewell AC; Wenzel D
    Acta Paediatr; 1996 Apr; 85(4):446-9. PubMed ID: 8740302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valproate therapy does not deplete carnitine levels in otherwise healthy children.
    Hirose S; Mitsudome A; Yasumoto S; Ogawa A; Muta Y; Tomoda Y
    Pediatrics; 1998 May; 101(5):E9. PubMed ID: 9565442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations in the carnitine metabolism in epileptic children treated with valproic acid.
    Chung S; Choi J; Hyun T; Rha Y; Bae C
    J Korean Med Sci; 1997 Dec; 12(6):553-8. PubMed ID: 9443096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. L-carnitine supplementation in childhood epilepsy: current perspectives.
    De Vivo DC; Bohan TP; Coulter DL; Dreifuss FE; Greenwood RS; Nordli DR; Shields WD; Stafstrom CE; Tein I
    Epilepsia; 1998 Nov; 39(11):1216-25. PubMed ID: 9821988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The problems of valproate therapy in severely handicapped children--valproate induced hyperammonemia and hypocarnitinemia].
    Matsui K; Iwamoto H; Ohtsuki N; Kobayashi T; Miyake S; Yamada M
    No To Hattatsu; 1991 Jan; 23(1):32-8. PubMed ID: 1825272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum carnitine during valproic acid therapy.
    Laub MC; Paetzke-Brunner I; Jaeger G
    Epilepsia; 1986; 27(5):559-62. PubMed ID: 3093213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction in blood free carnitine levels in association with changes in sodium valproate (VPA) disposition in epileptic patients treated with VPA and other anti-epileptic drugs.
    Hiraoka A; Arato T; Tominaga I
    Biol Pharm Bull; 1997 Jan; 20(1):91-3. PubMed ID: 9013816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carnitine metabolism in valproate-treated rats: the effect of L-carnitine supplementation.
    Nishida N; Sugimoto T; Araki A; Woo M; Sakane Y; Kobayashi Y
    Pediatr Res; 1987 Nov; 22(5):500-3. PubMed ID: 3120144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of L-carnitine supplementation on acute valproate intoxication.
    Murakami K; Sugimoto T; Woo M; Nishida N; Muro H
    Epilepsia; 1996 Jul; 37(7):687-9. PubMed ID: 8681902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of the effect of long term valproic acid treatment on plasma levels of carnitine, ammonia and amino acids related to the urea cycle in pediatric epileptic patients].
    Navarro-Quesada FJ; Lluch-Fernández MD; Vaquero-Abellán M; Marchante-Serrano C; Jiménez C
    Rev Neurol; 1997 Jul; 25(143):1037-44. PubMed ID: 9280630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The decreased level of plasma carnitine in patients with epilepsy].
    Belousova ED
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(6):106-110. PubMed ID: 28745680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carnitine disposition before and during valproate therapy in patients with epilepsy.
    Riva R; Albani F; Gobbi G; Santucci M; Baruzzi A
    Epilepsia; 1993; 34(1):184-7. PubMed ID: 8422857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diet- and valproate-induced transient hyperammonemia: effect of L-carnitine.
    Gidal BE; Inglese CM; Meyer JF; Pitterle ME; Antonopolous J; Rust RS
    Pediatr Neurol; 1997 May; 16(4):301-5. PubMed ID: 9258962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carnitine levels in valproic acid-treated psychiatric patients: a cross-sectional study.
    Moreno FA; Macey H; Schreiber B
    J Clin Psychiatry; 2005 May; 66(5):555-8. PubMed ID: 15986510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative systems pharmacology Model to characterize valproic acid-induced hyperammonemia and the effect of L-carnitine supplementation.
    Schiavo A; Maldonado C; Vázquez M; Fagiolino P; Trocóniz IF; Ibarra M
    Eur J Pharm Sci; 2023 Apr; 183():106399. PubMed ID: 36740101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.